SCHEMBL2853762

SCHEMBL2853762

S=[C]Nc1cc2ccccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.44
MAOB P27338 5/20 0.41
MAOA P21397 3/20 0.41
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
FLT3 P36888 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MGLL Q99685 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
ADRA2A P08913 1/20 0.39
CYP2D6 P10635 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
NISCH Q9Y2I1 1/20 0.39
TYR P14679 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969080 0.81 CYP2A6 (0.44) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL28643561 0.77 CYP2A6 (0.47) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL1419067 0.75 KDM4E (0.45) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL7699924 0.74 FLT3 (0.48) CYP2A6MAOBKDM4EHSD17B10FLT3
SCHEMBL24508880 0.71 RAB9A (0.49) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL8764646 0.71 CYP2D6 (0.51) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL13652068 0.70 ALDH1A1 (0.47) MAOBMAOAKDM4EHSD17B10FLT3
SCHEMBL2855183 0.69 CYP2A6 (0.64) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL30036439 0.69 MAOB (0.63) CYP2A6MAOBMAOAKDM4EHSD17B10
SCHEMBL103158 0.69 MAOB (0.63) CYP2A6MAOBMAOAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786079-B2 Substituted nonadepsipeptides AICURIS GMBH & CO. KG. (DE) 2010-08-31 US disclosed
EP-1809653-B1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2010-01-20 EP disclosed
US-20080058251-A1 Substituted nonadepsipeptides BAYER HEALTHCARE AG (DE) 2008-03-06 US disclosed
EP-1809653-A1 SUBSTITUTED NONADEPSIPEPTIDES AiCuris GmbH & Co. KG (DE) 2007-07-25 EP disclosed
WO-2006042654-A1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO. KG (DE) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058251-A1 Substituted nonadepsipeptides VIP, DNPEP, LNPEP CYP2A6 3442/4885MAOB 3376/4885MAOA 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.